Importantly, previous research demonstrates that ACAT inhibition reduces Aβ-induced neurotoxicity in vitro and AD pathology in FAD-Tg mouse models, including significant reductions in plaque burden and gliosis (reviewed in [69, 70]). The gene discussed is ACAT1; the disease is Alzheimer disease.